Brookline upgraded Rein Therapeutics (RNTX) to Buy from Hold with a $6 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNTX:
- Rein Therapeutics Resumes Phase 2 Trial for LTI-03
- Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03
- Rein Therapeutics Secures Third Pre-Paid Advance
- Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03
- Rein Therapeutics initiated with a Buy at H.C. Wainwright